AGTR1 and prostate cancer: AGT encodes angiotensinogen, part of the renin-angiotensin system (RAS), and precursor of Ang I. Angiotensin-converting enzyme (ACE) cleaves Ang I to biologically active Ang II, which on binding with its receptor (AT1R) regulates tissue inflammation.8–11 In a separate clinical cohort study, RC was seen in only 4.8% of patients with prostate cancer taking an ACE inhibitor (ACEi) during RT compared with 16.5% not taking an ACEi (P = .01; hazard ratio adjusted for clinical risk factors = 0.51, 95% CI 0.28-0.94), indicating that inhibition of ACE could protect against RT-induced bladder injury.12